Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
Standard
Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? / Seirafianpour, Farnoosh; Mozafarpoor, Samaneh; Fattahi, Nima; Sadeghzadeh-Bazargan, Afsaneh; Hanifiha, Melika; Goodarzi, Azadeh.
in: DERMATOL THER, Jahrgang 33, Nr. 4, 07.2020, S. e13733.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Kurzpublikation › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
AU - Seirafianpour, Farnoosh
AU - Mozafarpoor, Samaneh
AU - Fattahi, Nima
AU - Sadeghzadeh-Bazargan, Afsaneh
AU - Hanifiha, Melika
AU - Goodarzi, Azadeh
N1 - © 2020 Wiley Periodicals LLC.
PY - 2020/7
Y1 - 2020/7
N2 - The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences, and Google Scholar up to 20 March 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, antifibrosis, oxygenation, circulation, bronchodilator, ARDS, and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline on controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for COVID-19 treatment, especially as an adjuvant therapy in combination with other drugs.
AB - The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences, and Google Scholar up to 20 March 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, antifibrosis, oxygenation, circulation, bronchodilator, ARDS, and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline on controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for COVID-19 treatment, especially as an adjuvant therapy in combination with other drugs.
KW - Betacoronavirus
KW - COVID-19
KW - Chemotherapy, Adjuvant
KW - Coronavirus Infections/drug therapy
KW - Humans
KW - Pandemics
KW - Pentoxifylline/therapeutic use
KW - Phosphodiesterase Inhibitors/therapeutic use
KW - Pneumonia, Viral/drug therapy
KW - SARS-CoV-2
KW - COVID-19 Drug Treatment
U2 - 10.1111/dth.13733
DO - 10.1111/dth.13733
M3 - Short publication
C2 - 32473070
VL - 33
SP - e13733
JO - DERMATOL THER
JF - DERMATOL THER
SN - 1396-0296
IS - 4
ER -
